CVac, comprising a mannan carrier attached to mucin 1 (a tumor-specific cell surface protein) and autologous dendritic cells, last year demonstrated a statistically significant improvement in overall survival in a clinical trial in second-remission ovarian cancer. A European pilot trial against pancreatic cancer in remission was subsequently proposed.
Prima Shifts Focus To LAG-3 After Immutep Deal
The Australian immuno-therapeutics developer Prima BioMed has had a change of focus in recent months since buying Paris-based Immutep in late 2014. Prima’s lead product used to be its CVac cancer vaccine, but it has now shifted strategic priority to an LAG-3 immune checkpoint receptor that came with the acquisition.